A Phase I Clinical Trial of an Adenovirus-Mediated Endostatin Gene (E10A) in Patients with Solid Tumors

Xubin Lin, Huiqiang Huang, Su Li, Hongli Li, Yuhong Li, Ye Cao, Dongsheng Zhang, Yunfei Xia, Ying Guo, Wenlin Huang and Wen-Qi Jiang

volume 6 | issue 5

May 2007
Pages: 648 - 653

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Purpose

The purpose of the current study were to assess the safety and feasibility of repetitive intratumoral administration of E10A, an adenoviral vector encoding the wild-type endostatin gene, to patients with solid tumors, and to evaluate its biologic effect and the pharmacokinetics of endostatin.

Methods

Patients were treated with escalating doses from 1×10¹⁰ VP to 1×10¹² VP of E10A intratumorally on days 1 and 8. Patients were assessed for toxicity and viral shedding, and antitumor response was evaluated by imaging techniques and tumor biopsy. Circulating levels of endostatin were examined.

Results

Fifteen patients received 29 injections of E10A. No dose-limiting toxicity was developed, and the maximum tolerated dose had not yet been reached. Fever and local reaction of injection site were common, but rarely severe. Mild and transient hepatotoxicity was observed in one patient. Minor response of injected tumor was achieved and improvement of the control tumor was observed in one patient with nasopharyngeal carcinoma, and tumor necrosis was occurred in two patients. Sustained elevation of serum endostatin levels was detected.

Conclusion

Weekly intratumoral injection of up to 1×10¹² VP of E10A to patients with solid tumor is a feasible and well-tolerated procedure that exerts mild antitumor effects. A small and sustained elevation of endogenous endostatin in blood possibly has antitumor activity.